Toxicity Outcomes at 18 Months for Cs-131 Low-Dose-Rate Prostate Brachytherapy Compared to I-125 and Pd-103

被引：0
|
作者：
DePaoli, B. [1 ]
McVorran, S. M. [2 ]
Case, M. J. [3 ]
Khaleghi, S. [3 ]
Li, H. [3 ]
Marshall, D. T. [1 ]
机构：
[1] Med Univ South Carolina, Hollings Canc Ctr, Charleston, SC USA
[2] H Lee Moffitt Canc Ctr & Res Inst, Dept Radiat Oncol, Tampa, FL USA
[3] Med Univ South Carolina, Charleston, SC USA
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2022年 / 114卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2488
引用
收藏
页码：E218 / E218
页数：1
相关论文
共 50 条
  • [21] Outcomes of I-125 Low-Dose-Rate Brachytherapy in Patients with Localized Prostate Cancer: A Comprehensive Analysis from a Specialized Tertiary Referral Center
    Schubert, Philipp
    Strnad, Vratislav
    Hoefler, Daniel
    Schweizer, Claudia
    Putz, Florian
    Lotter, Michael
    Kreppner, Stephan
    Karius, Andre
    Fietkau, Rainer
    Merten, Ricarda
    JOURNAL OF PERSONALIZED MEDICINE, 2024, 14 (08):
  • [22] 125I low-dose-rate prostate brachytherapy and radical prostatectomy in patients with prostate cancer
    Zhou, Zhien
    Yan, Weigang
    Zhou, Yi
    Zhang, Fuquan
    Li, Hanzhong
    Ji, Zhigang
    ONCOLOGY LETTERS, 2019, 18 (01) : 72 - 80
  • [23] Shortcomings in published brachytherapy source parameters for accurate dose calculation for an eye plaque implant with I-125 or Pd-103 seeds
    Awan, S.
    Meigooni, A.
    Dini, S.
    Chen, Y.
    Khan, F.
    Cole, J.
    MEDICAL PHYSICS, 2007, 34 (06) : 2488 - 2489
  • [24] I-125 versus Pd-103 for low-risk prostate cancer: Morbidity outcomes from a prospective randomized multicenter trial
    Wallner, K
    Merrick, G
    True, L
    Cavanagh, W
    Simpson, C
    Butler, W
    CANCER JOURNAL, 2002, 8 (01): : 67 - 73
  • [25] Radiation protection and dosimetry issues for patients with prostate cancer after I-125 low-dose-rate brachytherapy permanent implant
    Licciardello, Tiziana
    Feliciani, Giacomo
    Mazzotti, Giorgio
    Mostacci, Domiziano
    Sarnelli, Anna
    Menghi, Enrico
    BRACHYTHERAPY, 2021, 20 (01) : 272 - 278
  • [26] Comparison of 131Cs, 103Pd and 125I isotopes in preplanning for permanent prostate brachytherapy
    Trichter, F.
    Furhang, E.
    Shasha, D.
    Ennis, R. D.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2006, 66 (03): : S700 - S700
  • [27] Dosimetric analysis of urinary morbidity following prostate brachytherapy (I-125 vs Pd-103) combined with external beam radiation therapy
    Chen, CT
    Waterman, FM
    Dicker, AP
    RADIOLOGY, 2000, 217 : 214 - 214
  • [28] Transperineal ultrasound guided I-125/Pd-103 brachytherapy for early stage prostate cancer: Update on clinical experience at seven years
    Grimm, PD
    Blasko, J
    Ragde, H
    Sylvester, J
    Cavanagh, W
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1997, 39 (02): : 219 - 219
  • [29] I-125 versus Pd-103 for low risk prostate cancer: Morbidity outcomes from a prospective randomized multi-center controlled trial
    Herstein, A
    Wallner, K
    Merrick, G
    Mitsuyama, P
    Armstrong, J
    True, L
    Cavanagh, W
    Butler, W
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2005, 63 (02): : S317 - S317
  • [30] Study for the radial dose function of 131Cs, 125I and 103Pd brachytherapy seeds sources
    Wang, Jian-Hua
    Qiu, Xiao-Ping
    Liu, Wei
    Xu, Xun-Jiang
    Hedianzixue Yu Tance Jishu/Nuclear Electronics and Detection Technology, 2007, 27 (06): : 1223 - 1226
12345